<p>GW&amp;K Investment Management LLC 在最近向證券交易委員會的披露中表示，在第三季度將其在 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - 免費報告) 的持股增加了 9.1%。該機構投資者在本季度購買了額外的 95,858 股後，持有該公司 1,144,330 股股票。GW&amp;K Investment Management LLC 在最近的報告期末持有的 Phathom Pharmaceuticals 的股份約佔 1.61%，價值 13,469,000 美元。</p>
<p>其他一些對沖基金和機構投資者最近也買賣了該公司的股票。Frazier Life Sciences Management L.P. 在第二季度將其在 Phathom Pharmaceuticals 的持股增加了 23.3%。Frazier Life Sciences Management L.P. 目前持有 12,466,489 股該公司的股票，價值 119,554,000 美元，此前在上個季度購買了額外的 2,357,210 股。Invesco Ltd. 在第二季度將其在 Phathom Pharmaceuticals 的股份增加了 13.4%。Invesco Ltd. 目前持有 4,140,072 股該公司的股票，價值 39,703,000 美元，此前在上個季度購買了額外的 489,260 股。Vanguard Group Inc. 在第三季度將其在 Phathom Pharmaceuticals 的持股增加了 15.4%。Vanguard Group Inc. 目前持有 3,215,572 股該公司的股票，價值 37,847,000 美元，此前在上個季度購買了額外的 428,261 股。683 Capital Management LLC 在第二季度將其在 Phathom Pharmaceuticals 的持股增加了 45.7%。683 Capital Management LLC 目前持有 2,105,000 股該公司的股票，價值 20,187,000 美元，此前在上個季度購買了額外的 660,000 股。最後，Geode Capital Management LLC 在第二季度將其在 Phathom Pharmaceuticals 的股份增加了 5.3%。Geode Capital Management LLC 目前持有 1,069,927 股該公司的股票，價值 10,263,000 美元，此前在此期間購買了額外的 53,504 股。機構投資者持有該公司 99.01% 的股份。</p>
<h2>Phathom Pharmaceuticals 股票下跌 0.7%</h2>
<p>NASDAQ:PHAT 的股票週五開盤價為 10.67 美元。Phathom Pharmaceuticals, Inc. 的 12 個月最低價為 2.21 美元，最高價為 18.31 美元。該股票的 50 日移動平均線為 13.62 美元，200 日移動平均線為 13.50 美元。該公司的市值為 8.408 億美元，市盈率為 -3.49，貝塔值為 0.51。</p>
<p>Phathom Pharmaceuticals (NASDAQ:PHAT - 獲取免費報告) 最近在 2 月 26 日星期四公佈了季度財報。該公司報告本季度每股收益為（0.08）美元，超出分析師的共識預期（0.09）美元 0.01 美元。該公司的季度收入為 5758 萬美元，而共識預期為 5744 萬美元。股票研究分析師預計 Phathom Pharmaceuticals, Inc. 在當前財政年度將發佈 -4.78 的每股收益。</p>
<h2>華爾街分析師觀點</h2>
<p>PHAT 已成為幾份分析師報告的主題。Stifel Nicolaus 在 2 月 26 日星期四的研究報告中將 Phathom Pharmaceuticals 的目標價設定為 28.00 美元。Guggenheim 在 2 月 27 日星期五的研究報告中將 Phathom Pharmaceuticals 的目標價從 20.00 美元上調至 25.00 美元，並給予該股票 &#34;買入&#34; 評級。Raymond James Financial 在 12 月 11 日星期四對 Phathom Pharmaceuticals 開始覆蓋。他們對該股票給予了 &#34;強力買入&#34; 評級，並設定了 28.00 美元的目標價。Weiss Ratings 在 1 月 22 日星期四的報告中重申了對 Phathom Pharmaceuticals 股票的 &#34;賣出（d-）&#34; 評級。最後，Cantor Fitzgerald 在 1 月 14 日星期三的研究報告中重申了對 Phathom Pharmaceuticals 股票的 &#34;增持&#34; 評級。一位投資分析師對該股票給予了強力買入評級，五位給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票的共識評級為 &#34;適度買入&#34;，共識目標價為 22.25 美元。</p>
<p><strong>查看我們關於 PHAT 的最新股票報告</strong></p>
<h2>關於 Phathom Pharmaceuticals</h2>
<p>（免費報告）</p>
<p>Phathom Pharmaceuticals 是一家臨牀階段的生物製藥公司，專注於開發和商業化針對胃腸道（GI）疾病的新型治療方法。該公司的核心使命是通過利用創新的作用機制來改善患者的治療效果，從而解決嚴重的胃腸道疾病。Phathom 的研發工作集中在如幽門螺桿菌感染、侵蝕性食管炎、胃輕癱及其他功能性胃腸道疾病等存在重大未滿足醫療需求的病症上。</p>
<p>該公司的主要資產是 vonoprazan，一種鉀競爭性酸阻滯劑（P-CAB），已在美國獲得使用許可。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Phathom Pharmaceuticals</li>
<li>華爾街害怕的黃金圖表……</li>
<li>美國的 1776 再次發生</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
<li>埃隆·馬斯克已經讓我成為一個 “富有的人”</li>
</ul>
<p><strong>想看看其他對沖基金持有的 PHAT 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - 免費報告) 的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEhBVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEhBVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Phathom Pharmaceuticals 嗎？</h2>
<p>在你考慮投資 Phathom Pharmaceuticals 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Phathom Pharmaceuticals 並不在名單上。</p>
<p>雖然 Phathom Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

納斯達克生物科技指數 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

標普生物技術 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 3 倍做空 - Direxion

動態生物技術與基因組 ETF - Invesco

PHAT

<p>GW&K Investment Management LLC 在第三季度將其在 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) 的持股增加了 9.1%，目前持有 1,144,330 股，價值約為 1347 萬美元。其他機構投資者也增加了他們的持股，其中 Frazier Life Sciences Management L.P. 增加了 23.3%。Phathom 的股票目前下跌 0.7%，交易價格為 10.67 美元，市值為 8.408 億美元。分析師的評級意見不一，普遍目標價為 22.25 美元。Phathom 專注於開發胃腸疾病的治療方案，其主要資產為 vonoprazan</p>

<p>GW&amp;K Investment Management LLC boosted its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 9.1% during the 3rd quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor owned 1,144,330 shares of the company's stock after buying an additional 95,858 shares during the quarter. GW&amp;K Investment Management LLC owned approximately 1.61% of Phathom Pharmaceuticals worth $13,469,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>GW&amp;K Investment Management LLC 在最近向證券交易委員會的披露中表示，在第三季度將其在 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - 免費報告) 的持股增加了 9.1%。該機構投資者在本季度購買了額外的 95,858 股後，持有該公司 1,144,330 股股票。GW&amp;K Investment Management LLC 在最近的報告期末持有的 Phathom Pharmaceuticals 的股份約佔 1.61%，價值 13,469,000 美元。</p>
</div><p>A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Frazier Life Sciences Management L.P. increased its holdings in Phathom Pharmaceuticals by 23.3% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 12,466,489 shares of the company's stock worth $119,554,000 after purchasing an additional 2,357,210 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Phathom Pharmaceuticals by 13.4% during the second quarter. Invesco Ltd. now owns 4,140,072 shares of the company's stock valued at $39,703,000 after purchasing an additional 489,260 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Phathom Pharmaceuticals by 15.4% during the third quarter. Vanguard Group Inc. now owns 3,215,572 shares of the company's stock worth $37,847,000 after purchasing an additional 428,261 shares during the last quarter. 683 Capital Management LLC grew its holdings in shares of Phathom Pharmaceuticals by 45.7% during the second quarter. 683 Capital Management LLC now owns 2,105,000 shares of the company's stock worth $20,187,000 after purchasing an additional 660,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Phathom Pharmaceuticals by 5.3% in the second quarter. Geode Capital Management LLC now owns 1,069,927 shares of the company's stock valued at $10,263,000 after buying an additional 53,504 shares during the period. Institutional investors own 99.01% of the company's stock.</p>
<div class="lb-trans"><p>其他一些對沖基金和機構投資者最近也買賣了該公司的股票。Frazier Life Sciences Management L.P. 在第二季度將其在 Phathom Pharmaceuticals 的持股增加了 23.3%。Frazier Life Sciences Management L.P. 目前持有 12,466,489 股該公司的股票，價值 119,554,000 美元，此前在上個季度購買了額外的 2,357,210 股。Invesco Ltd. 在第二季度將其在 Phathom Pharmaceuticals 的股份增加了 13.4%。Invesco Ltd. 目前持有 4,140,072 股該公司的股票，價值 39,703,000 美元，此前在上個季度購買了額外的 489,260 股。Vanguard Group Inc. 在第三季度將其在 Phathom Pharmaceuticals 的持股增加了 15.4%。Vanguard Group Inc. 目前持有 3,215,572 股該公司的股票，價值 37,847,000 美元，此前在上個季度購買了額外的 428,261 股。683 Capital Management LLC 在第二季度將其在 Phathom Pharmaceuticals 的持股增加了 45.7%。683 Capital Management LLC 目前持有 2,105,000 股該公司的股票，價值 20,187,000 美元，此前在上個季度購買了額外的 660,000 股。最後，Geode Capital Management LLC 在第二季度將其在 Phathom Pharmaceuticals 的股份增加了 5.3%。Geode Capital Management LLC 目前持有 1,069,927 股該公司的股票，價值 10,263,000 美元，此前在此期間購買了額外的 53,504 股。機構投資者持有該公司 99.01% 的股份。</p>
</div><h2>Phathom Pharmaceuticals Stock Down 0.7%</h2>
<div class="lb-trans"><h2>Phathom Pharmaceuticals 股票下跌 0.7%</h2>
</div><p>Shares of NASDAQ:PHAT opened at $10.67 on Friday. Phathom Pharmaceuticals, Inc. has a twelve month low of $2.21 and a twelve month high of $18.31. The stock's 50 day moving average is $13.62 and its 200-day moving average is $13.50. The firm has a market capitalization of $840.80 million, a price-to-earnings ratio of -3.49 and a beta of 0.51.</p>
<div class="lb-trans"><p>NASDAQ:PHAT 的股票週五開盤價為 10.67 美元。Phathom Pharmaceuticals, Inc. 的 12 個月最低價為 2.21 美元，最高價為 18.31 美元。該股票的 50 日移動平均線為 13.62 美元，200 日移動平均線為 13.50 美元。該公司的市值為 8.408 億美元，市盈率為 -3.49，貝塔值為 0.51。</p>
</div><p>Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. The business had revenue of $57.58 million for the quarter, compared to the consensus estimate of $57.44 million. Equities research analysts anticipate that Phathom Pharmaceuticals, Inc. will post -4.78 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Phathom Pharmaceuticals (NASDAQ:PHAT - 獲取免費報告) 最近在 2 月 26 日星期四公佈了季度財報。該公司報告本季度每股收益為（0.08）美元，超出分析師的共識預期（0.09）美元 0.01 美元。該公司的季度收入為 5758 萬美元，而共識預期為 5744 萬美元。股票研究分析師預計 Phathom Pharmaceuticals, Inc. 在當前財政年度將發佈 -4.78 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>PHAT has been the subject of several analyst reports. Stifel Nicolaus set a $28.00 target price on Phathom Pharmaceuticals in a research report on Thursday, February 26th. Guggenheim raised their price objective on Phathom Pharmaceuticals from $20.00 to $25.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, February 27th. Raymond James Financial assumed coverage on Phathom Pharmaceuticals in a report on Thursday, December 11th. They issued a &#34;strong-buy&#34; rating and a $28.00 target price on the stock. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Phathom Pharmaceuticals in a report on Thursday, January 22nd. Finally, Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $22.25.</p>
<div class="lb-trans"><p>PHAT 已成為幾份分析師報告的主題。Stifel Nicolaus 在 2 月 26 日星期四的研究報告中將 Phathom Pharmaceuticals 的目標價設定為 28.00 美元。Guggenheim 在 2 月 27 日星期五的研究報告中將 Phathom Pharmaceuticals 的目標價從 20.00 美元上調至 25.00 美元，並給予該股票 &#34;買入&#34; 評級。Raymond James Financial 在 12 月 11 日星期四對 Phathom Pharmaceuticals 開始覆蓋。他們對該股票給予了 &#34;強力買入&#34; 評級，並設定了 28.00 美元的目標價。Weiss Ratings 在 1 月 22 日星期四的報告中重申了對 Phathom Pharmaceuticals 股票的 &#34;賣出（d-）&#34; 評級。最後，Cantor Fitzgerald 在 1 月 14 日星期三的研究報告中重申了對 Phathom Pharmaceuticals 股票的 &#34;增持&#34; 評級。一位投資分析師對該股票給予了強力買入評級，五位給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票的共識評級為 &#34;適度買入&#34;，共識目標價為 22.25 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on PHAT</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 PHAT 的最新股票報告</strong></p>
</div><h2>About Phathom Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Phathom Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company's core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom's research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.</p>
<div class="lb-trans"><p>Phathom Pharmaceuticals 是一家臨牀階段的生物製藥公司，專注於開發和商業化針對胃腸道（GI）疾病的新型治療方法。該公司的核心使命是通過利用創新的作用機制來改善患者的治療效果，從而解決嚴重的胃腸道疾病。Phathom 的研發工作集中在如幽門螺桿菌感染、侵蝕性食管炎、胃輕癱及其他功能性胃腸道疾病等存在重大未滿足醫療需求的病症上。</p>
</div><p>The company's lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.</p>
<div class="lb-trans"><p>該公司的主要資產是 vonoprazan，一種鉀競爭性酸阻滯劑（P-CAB），已在美國獲得使用許可。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Phathom Pharmaceuticals</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>Elon Musk already made me a “wealthy man”</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Phathom Pharmaceuticals</li>
<li>華爾街害怕的黃金圖表……</li>
<li>美國的 1776 再次發生</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
<li>埃隆·馬斯克已經讓我成為一個 “富有的人”</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PHAT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 PHAT 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - 免費報告) 的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEhBVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PHAT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Phathom Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Phathom Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Phathom Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Phathom Pharmaceuticals 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Phathom Pharmaceuticals 並不在名單上。</p>
</div><p>While Phathom Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Phathom Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

GW&K Investment Management LLC Has $13.47 Million Stock Position in Phathom Pharmaceuticals, Inc. $PHAT

Market Beat

Phathom Pharmaceuticals

GW&K Investment Management LLC 在 Phathom Pharmaceuticals, Inc. $PHAT 持有價值 1347 萬美元的股票頭寸